Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill for ulcerative colitis shows promise, but trial halted early

NCT ID NCT05785715

Terminated Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 19, 2026 · Last updated Jun 22, 2026 · Updated 1 time

Summary

This study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the data may still help researchers understand if NX-13 can safely control disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AmiCare Centrum Medyczne

    Jelenia Góra, Poland

  • AmiCare Sp. z o.o. Sp.k.

    Lodz, Poland

  • Amicare Sp z o.o. S.K

    Opoczno, Poland

  • Azienda Ospedaliera - Universitaria Sant' Andrea

    Roma, Italy

  • Azienda Ospedaliera Ordine Mauriziano di Torino

    Torino, Italy

  • Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.

    Wroclaw, Poland

  • Centrum Diagnostyczno - Lecznicze Barska

    Włocławek, Poland

  • ClinSante - Ośrodek Badań Klinicznych w Bydgoszczy

    Bydgoszcz, Poland

  • Clinical Research Institute of Michigan

    Troy, Michigan, 48098, United States

  • Digestive Disease Specialist, Inc-INTEGRIS Baptist Medical Center

    Oklahoma City, Oklahoma, 73112, United States

  • Digestive Health Associates of Texas-GI Alliance

    Mansfield, Texas, 76003, United States

  • Digestive Health Associates of Texas-GI Alliance Research-Garland

    Garland, Texas, 75044, United States

  • Digestive Health Center of Michigan

    Chesterfield, Michigan, 48047, United States

  • Endoskopia Sp. z o.o.

    Sopot, Poland

  • GCP Clinical Research

    Tampa, Florida, 33609, United States

  • H-T Centrum Medyczne

    Tychy, Poland

  • IRCCS Fondazione Casa Sollievo della Sofferenza SG Rotondo

    San Giovanni Rotondo, Italy

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas

    Rozzano, Italy

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

    Milan, Italy

  • Krakowska Przychodnia FutureMeds

    Krakow, Poland

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Miami Clinical Research

    Miami, Florida, 33155, United States

  • Office of Jaroslaw Kierkus, Dr N Med

    Warsaw, Poland

  • Orlando Health, Inc.

    Orlando, Florida, 32806, United States

  • Przychodnia Vitamed NFZ

    Bydgoszcz, Poland

  • RiverMED Poradnie Specjalistyczne Poznań

    Poznan, Poland

  • Sonomed Sp. z o.o. Centrum Medyczne

    Szczecin, Poland

  • Texas Digestive Disease Consultants-GI Alliance Research

    Southlake, Texas, 76092, United States

  • Torunskiego Centrum Gastrologii I Endoskopii - Gastromed

    Torun, Poland

  • Twoja Przychodnia Opolskie Centrum Medyczne

    Opole, Poland

  • Twoja Przychodnia Szczecińskie Centrum Medyczne

    Szczecin, Poland

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • VITA LONGA Clinic - Katowice

    Katowice, Poland

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri, 63110, United States

  • Zabobrze Centrum Medyczne

    Wroclaw, Poland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NX-13 (oral tablet)

What this could lead to

If successful, NX-13 could offer a new oral treatment option to help control moderate to severe ulcerative colitis.

What could go wrong

This early-phase trial was terminated, so results are limited. It is unclear if NX-13 is effective or safe; more research is needed.

Conditions

The condition(s) this trial relates to.

follicular lymphoma ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS